NRG Energy Inc. Stock Slides 4.3%, Underperforms Peers
Dow Jones2026/08/20 20:35This article was automatically generated by Dow Jones using technology from Automated Insights.
Shares of NRG Energy Inc. slipped 4.3% to $115.36 on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index falling 0.9% to 7,641.16 and Dow Jones Industrial Average falling 1.3% to 52,759.21.
NRG Energy Inc. closed 39.3% short of its 52-week high of $189.96, which the company reached on February 25th.
The stock underperformed when compared to some of its peers, as Duke Energy Corp. fell 0.7% to $122.69, Exelon Corp. fell 0.5% to $45.06, and Sempra rose 2.09% to $87.38.
Trading volume totaled 2.8 million, compared to the 50-day average of 2.8 million.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
August 20, 2026 16:35 ET (20:35 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.
Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.

WTI Price Forecast: Slides further below $100.50; bullish potential seems intact
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.
Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.
